No Data
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Savara Management to Meet Virtually With Piper Sandler
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Evercore ISI Remains a Buy on Savara (SVRA)
Savara Announces Patient Journey Map for People Living With Autoimmune Pulmonary Alveolar Proteinosis (APAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting